About this course

  • Released: 11/27/2017
  • Expires: 11/27/2019

Instructions

  • Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
  • Study the educational activity
  • Complete the CME quiz and evaluation
  • After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

*The CME quiz and evaluation must be completed by November 27, 2019 in order to receive the credit or participation certificate.

Target Audience

Physicians who wish to advance their current knowledge of breast cancer.

Learning Objectives

  1. Discuss the increasing incidence of male breast cancer, both as an initial cancer and as a second cancer following another malignancy.
  2. Cite possible causes underlying the association of male breast cancer with earlier lymphoma, including biology, treatment effects, and genetic factors.

Accreditation and Credit Designation

The Society for Translational Oncology is accredited by the ACCME to provide continuing medical education for physicians.

The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

In compliance with the ACCME Standards of Commercial Support, it is the policy of the Society for Translational Oncology to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities and to include information free of commercial bias and based on the best evidence available. All individuals in a position to influence the content of this activity have disclosed relevant financial interests or relationships of their own, their spouse/partner, or their worksite, with manufacturers or providers of commercial products, services, technology, or programs; and disclosed relationships with current non-governmental supporters of the activity.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://authors.theoncologist.com/conflicts-of-interest. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Author Disclosure(s)

Deborah E. Farr

Division of Surgical Oncology, UT Southwestern Medical Center, Dallas, Texas, USA

The author discloses no relevant financial relationships.

Alexandra Thomas

Department of Internal Medicine, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina, USA

The author discloses no relevant financial relationships.

Seema Ahsan Khan

Department of Surgery, Feinberg School of Medicine of Northwestern University, Chicago, Illinois, USA

The author discloses no relevant financial relationships.

Mary C. Schroeder

Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, Iowa, USA

The author discloses no relevant financial relationships.

 

Section Editors Disclosures

Gabriel Hortobágyi discloses consulting relationships with Bayer, Lilly, Metastat, Merck, Novartis, Peregrine Pharmaceuticals, and Roche, research funding received from Novartis, and an ownership interest in Taivex.

Kathleen Pritchard discloses consulting relationships with and honoraria received from Novartis, Roche, AstraZeneca, Pfizer, GlaxoSmithKline, Amgen, and Eisai.

 

Independent Peer Reviewers Disclosures

Reviewer 1 discloses no relevant financial relationships.

 

CME Program Editor Disclosures

Jayne S. Gurtler, M.D., F.A.C.P., CME Program Editor, East Jefferson General Hospital, Metairie, Louisiana, discloses research funding from Chiltern, EMD Serono, Merck, Novartis, and TransCelerate.

 

Staff Planners Disclosures

No financial relationships relevant to the content of this article have been disclosed by the staff planners.

 

Commercial Support

The Editors are grateful for educational grants from Incyte and Merrimack in partial support of our Journal CME Program.

 

Other Links

Disclaimer Privacy statement

Correspondence

The Oncologist CME Online
318 Blackwell Street, Suite 270
Durham, North Carolina 27701
Phone: (919) 433-0489
Fax: (919) 680-4411
Email: CME@TheOncologist.com